CRL · Earnings call · 2026Q2T · Full report
Manufacturing And Capacity
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Charles River is expanding bioanalytical laboratory capacity at Heriot-Watt University’s Research Park in Scotland. The Scotland project is one of five lab-sciences expansions underway globally and includes a potential partnership with Heriot-Watt University to strengthen the regional talent pipeline. Management said current DSA in vivo capacity, including animal rooms and equipment, is sufficient to absorb near-term growth, with staffing adjustments manageable as volumes rise. Additional laboratory expansions are needed over the next several years to support growth at or above the market rate, although management does not currently see a capacity bottleneck.
Key facts
- Charles River expects the Manufacturing segment operating margin to approach 40% in the second half of the year with full benefit recognized from the CDMO divestiture.
- Charles River stated they have sufficient DSA capacity currently due to prior volume declines but will need to execute on lab expansions over the next couple of years to grow with or above the market.
- The CDMO business reduced the Manufacturing segment organic revenue growth rate by nearly 400 basis points in the quarter; excluding CDMO, the segment grew at a mid-single-digit organic growth rate.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| margin | positive | committed | — | Charles River expects the Manufacturing segment operating margin to approach 40% in the second half of the year with full benefit… |
| assets | positive | probable | — | Charles River stated they have sufficient DSA capacity currently due to prior volume declines but will need to execute on lab expansions… |
| cash | negative | probable | — | Charles River stated they have sufficient DSA capacity currently due to prior volume declines but will need to execute on lab expansions… |